Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Snape

Showing results (141-150 of 169) with videos related to

Pageof 17
Sort By:
JAMA|April 20, 2016
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical TrialIain D Milligan, Malick M Gibani, Richard Sewell, et al.
Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.
The Lancet. Infectious Diseases|January 22, 2021
Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey resultsJenny M MacLennan, Charlene M C Rodrigues, Holly B Bratcher, et al.
Frontiers in Immunology|July 17, 2020
Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus StatementBahaa Abu-Raya, Kirsten Maertens, Kathryn M Edwards, et al.
The Journal of Infectious Diseases|July 16, 2024
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in CommunitiesDima El Safadi, Lisa Hitchins, Ashleigh Howard, et al.
Science Immunology|August 29, 2025
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccinesAli Amini, Lucy C Garner, Robert H Shaw, et al.
The Journal of Infection|June 18, 2023
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trialEimear Kelly, Melanie Greenland, Philip C S de Whalley, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
Pageof 17

Showing results (141-150 of 169) with videos related to

Sort By:
Pageof 17
JAMA|April 20, 2016
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical TrialIain D Milligan, Malick M Gibani, Richard Sewell, et al.
Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.
The Lancet. Infectious Diseases|January 22, 2021
Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey resultsJenny M MacLennan, Charlene M C Rodrigues, Holly B Bratcher, et al.
Frontiers in Immunology|July 17, 2020
Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus StatementBahaa Abu-Raya, Kirsten Maertens, Kathryn M Edwards, et al.
The Journal of Infectious Diseases|July 16, 2024
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in CommunitiesDima El Safadi, Lisa Hitchins, Ashleigh Howard, et al.
Science Immunology|August 29, 2025
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccinesAli Amini, Lucy C Garner, Robert H Shaw, et al.
The Journal of Infection|June 18, 2023
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trialEimear Kelly, Melanie Greenland, Philip C S de Whalley, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
Pageof 17